文献速递消化道肿瘤与早癌消化内镜

基于cfDNA片段组学的新型结直肠癌血液检测

A Novel Blood-Based Test for Colorectal Cancer Detection Using Cell-Free DNA Fragmentomics.
PubMed 文献 · Am J Gastroenterol · 2025-11-19

该前瞻性病例对照研究纳入1677例受试者,利用cfDNA片段组学特征构建诊断模型,在验证队列中检测结直肠癌的敏感性为90.4%,进展期腺瘤为58.3%,正常结肠镜者特异性为94.7%。

要点

  • cfDNA片段组学血液检测对结直肠癌敏感性达90.4%,特异性94.7%。
  • 对进展期腺瘤敏感性58.3%,准确性可接受。
  • 各分期及左右半结肠癌检测性能一致。

核心结论

  • 基于cfDNA片段组学的血液检测对结直肠癌具有高诊断准确性,对进展期腺瘤性能可接受。

研究设计与样本

  • 前瞻性病例对照研究,纳入1677例受试者,随机分为开发队列1250例和验证队列427例,对cfDNA进行全基因组测序提取片段组学特征。

主要发现

  • 验证队列中结直肠癌敏感性90.4%(95%CI 82.2-97.3),进展期腺瘤敏感性58.3%(95%CI 48.1-67.6)。
  • 进展期肿瘤总体准确性84.8%(95%CI 81.1-87.8),正常结肠镜者特异性94.7%(95%CI 91.2-96.9)。
  • 结直肠癌AUC为0.978,进展期腺瘤AUC为0.862。
  • 结直肠癌各分期敏感性:I期84.2%,II期85.0%,III期94.4%,IV期100.0%。
  • 检测性能在肿瘤部位、年龄亚组及进展期腺瘤部位间一致。

临床怎么用

  • 该血液检测可作为结直肠癌无创筛查的潜在工具,尤其适用于拒绝或无法进行结肠镜检查的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA). METHODS: In this prospective case-control study, 1,677 participants were enrolled: 1,267 with normal colonoscopy, 302 with CRC, and 108 with AA. Participants were randomly assigned to either a development cohort (n = 1,250) or a validation cohort (n = 427). Whole-genome sequencing of cfDNA was performed to extract fragmentomic features, including end motifs, fragment lengths, and genome-wide coverage. A diagnostic model was developed using the Residual Enrichment From Independent Normal Ensemble method, and its performance was assessed in the validation cohort. RESULTS: In the validation cohort, the sensitivities for CRC and AA were 90.4% (95% CI, 82.2-97.3) and 58.3% (95% CI, 48.1-67.6), respectively. Overall accuracy for advanced neoplasia was 84.8% (95% CI, 81.1-87.8), and specificity in individuals with normal colonoscopy was 94.7% (95% CI, 91.2-96.9). The areas under the receiver operating characteristic curve were 0.978 for CRC and 0.862 for AA. Sensitivities by CRC stage were 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV). Diagnostic performance was consistent across CRC locations (left vs right colon), age of patients with CRC (<60 vs ≥60), and AA locations. DISCUSSION: This cfDNA-based blood test demonstrated high diagnostic accuracy for CRC and acceptable performance for AA. Its consistent performance across clinical subgroups suggests its potential as an effective noninvasive CRC screening tool.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hong SW, Park J, Lee J, et al. A Novel Blood-Based Test for Colorectal Cancer Detection Using Cell-Free DNA Fragmentomics. Am J Gastroenterol. 2025. PMID: 41257520. doi:10.14309/ajg.0000000000003856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。